Massenkeil G, Gropp C, Kreipe H, Hussein K
Klinik für Innere Medizin, Klinikum Gütersloh, Reckenberger Straße 19, 33332, Gütersloh, Deutschland.
Onkologische Gemeinschaftspraxis, Gütersloh, Deutschland.
Pathologe. 2017 Jul;38(4):317-323. doi: 10.1007/s00292-017-0300-2.
Bone marrow carcinosis is a sign of advanced tumor stage with nonspecific clinical and hematological symptoms. Diagnosis is based on bone marrow biopsy and histopathology, but biopsies are not part of the standard work-up in oncological diseases and data on the correlation between clinical presentation and pathological findings are sparse.
In a retrospective single-center study, data from 20 tumor patients with bone marrow carcinosis were analyzed. Bone marrow biopsies were re-evaluated regarding quantity of tumor cells, fibrosis/necrosis, and bone changes. Immunohistochemistry of potential therapy-relevant receptors and PD-L1 was performed.
The median age in these 20 patients (13 women, 7 men) was 65 years. The most frequent diagnoses were breast (n = 8) and lung cancer (n = 5). Anemia (94% of patients), thrombocytopenia (72%), and elevated LDH (83%) were frequent findings. The degree of bone marrow infiltration was highly variable and accounted for between 1 and 95% of biopsy space. Significant bone remodeling was present in 14/20 biopsies. No correlation could be found between histological and radiological findings. Treated patients showed some clinical and biochemical improvement, but the overall survival was poor (median 4.5 months, range < 0.5 to 21.5 months).
Anemia and thrombocytopenia are frequently associated with bone marrow carcinosis, but are nonspecific. The extent of tumor cell infiltration and osteolytic/osteoblastic changes did not correlate with radiological findings. Therapy-relevant target factors should be evaluated, but therapeutic options are often limited and the prognosis is bad.
骨髓转移癌是肿瘤晚期的一个征象,伴有非特异性的临床和血液学症状。诊断基于骨髓活检和组织病理学检查,但活检并非肿瘤性疾病标准检查的一部分,且关于临床表现与病理结果之间相关性的数据较少。
在一项回顾性单中心研究中,分析了20例患有骨髓转移癌的肿瘤患者的数据。对骨髓活检标本重新评估肿瘤细胞数量、纤维化/坏死情况以及骨质改变。对潜在治疗相关受体和程序性死亡受体配体1(PD-L1)进行免疫组织化学检测。
这20例患者(13例女性,7例男性)的中位年龄为65岁。最常见的诊断是乳腺癌(n = 8)和肺癌(n = 5)。常见的表现有贫血(94%的患者)、血小板减少(72%)和乳酸脱氢酶升高(83%)。骨髓浸润程度差异很大,占活检组织面积的1%至95%。20份活检标本中有14份存在明显的骨质重塑。未发现组织学和影像学检查结果之间存在相关性。接受治疗的患者在临床和生化指标上有一定改善,但总体生存期较差(中位生存期4.5个月,范围<0.5至21.5个月)。
贫血和血小板减少常与骨髓转移癌相关,但缺乏特异性。肿瘤细胞浸润程度和溶骨/成骨改变与影像学检查结果无关。应评估与治疗相关的靶标因素,但治疗选择往往有限,预后较差。